PT-141

FDA Approved

Bremelanotide

Category
Sexual Health
Aliases
Bremelanotide, Vyleesi
Administration
Subcutaneous injection (approved), Intranasal (research)

Overview

First FDA-approved non-hormonal treatment for hypoactive sexual desire disorder. Acts centrally via melanocortin receptors — entirely distinct from vascular-based sexual dysfunction drugs.

Treatments studied

Treatment categories

Erectile dysfunction (off-label)

Acts centrally on brain arousal pathways rather than on blood flow, offering an alternative mechanism to PDE5 inhibitors.

Hypoactive sexual desire disorder

The only FDA-approved use, treating low sexual desire through direct melanocortin receptor activation in the brain.

Sexual dysfunction

Addresses the neurological component of arousal rather than the vascular component alone.